5am Ventures v sells Entrada Therapeutics (TRDA) stock for $202k

5AM Ventures V, a ten percent owner in Entrada Therapeutics , Inc. (NASDAQ:TRDA), a $238.33 million market cap biotech company, reported selling 27,000 shares of common stock on July 9, 2025. The transaction comes as the stock trades near its 52-week low of $6.48, having declined over 55% in the past six months. According to InvestingPro analysis, the stock appears undervalued at current levels. The sales, executed at a price of $7.502 per share, totaled $202,554.

Specifically, 5AM Ventures V, L.P. sold 20,065 shares directly, while 5AM Opportunities I, L.P. sold 6,935 shares.

Following the transactions, 5AM Ventures V, L.P. directly holds 3,163,066 shares of Entrada Therapeutics. 5AM Opportunities I, L.P. indirectly holds 1,093,313 shares.

In other recent news, Entrada Therapeutics has received regulatory approvals to commence a new clinical study in Europe and the United Kingdom (TADAWUL:4280). This authorization allows the company to initiate the ELEVATE-45-201 Phase 1/2 clinical study, focusing on ENTR-601-45 for patients with Duchenne muscular dystrophy (DMD) amenable to exon 45 skipping. The study, set to begin in the third quarter of 2025, will evaluate the safety, tolerability, and effectiveness of the drug in approximately 24 ambulatory DMD patients. The clinical trial is a significant move for Entrada, as it follows the authorization from the Medicines and Healthcare Products Regulatory Agency in the UK. The study will be conducted in two parts, focusing first on safety and optimal dosing, and then on the drug’s efficacy. Additionally, Entrada plans to submit global regulatory applications for other exon-skipping candidates, ENTR-601-50 and ENTR-601-51, in the coming years. Analysts at H.C. Wainwright have reaffirmed a Buy rating on Entrada Therapeutics, maintaining a price target of $20.00. This decision aligns with the company’s strategic efforts to advance its pipeline of therapeutics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.